iX Biopharma Statistics

Total Valuation

iX Biopharma has a market cap or net worth of SGD 20.32 million. The enterprise value is 23.67 million.

Market Cap	20.32M
Enterprise Value	23.67M

Important Dates

The next estimated earnings date is Tuesday, February 4, 2025.

Earnings Date	Feb 4, 2025
Ex-Dividend Date	n/a

Share Statistics

iX Biopharma has 883.34 million shares outstanding. The number of shares has increased by 0.33% in one year.

Current Share Class	n/a
Shares Outstanding	883.34M
Shares Change (YoY)	+0.33%
Shares Change (QoQ)	+0.25%
Owned by Insiders (%)	44.54%
Owned by Institutions (%)	0.10%
Float	457.91M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	2.96
PB Ratio	4.07
P/TBV Ratio	5.02
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-2.19
EV / Sales	3.97
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-3.47

Financial Position

The company has a current ratio of 0.89, with a Debt / Equity ratio of 1.20.

Current Ratio	0.89
Quick Ratio	0.65
Debt / Equity	1.20
Debt / EBITDA	n/a
Debt / FCF	-0.76
Interest Coverage	-16.96

Financial Efficiency

Return on equity (ROE) is -106.91% and return on invested capital (ROIC) is -31.51%.

Return on Equity (ROE)	-106.91%
Return on Assets (ROA)	-23.69%
Return on Capital (ROIC)	-31.51%
Revenue Per Employee	141,881
Profits Per Employee	-257,000
Employee Count	42
Asset Turnover	0.30
Inventory Turnover	4.20

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -47.73% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-47.73%
50-Day Moving Average	0.02
200-Day Moving Average	0.03
Relative Strength Index (RSI)	45.32
Average Volume (20 Days)	89,015

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, iX Biopharma had revenue of SGD 5.96 million and -10.79 million in losses. Loss per share was -0.01.

Revenue	5.96M
Gross Profit	1.05M
Operating Income	-7.50M
Pretax Income	-9.99M
Net Income	-10.79M
EBITDA	-7.08M
EBIT	-7.50M
Loss Per Share	-0.01

Full Income Statement

Balance Sheet

The company has 1.84 million in cash and 5.20 million in debt, giving a net cash position of -3.36 million or -0.00 per share.

Cash & Cash Equivalents	1.84M
Total Debt	5.20M
Net Cash	-3.36M
Net Cash Per Share	-0.00
Equity (Book Value)	4.34M
Book Value Per Share	0.01
Working Capital	-795,000

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -6.55 million and capital expenditures -274,000, giving a free cash flow of -6.83 million.

Operating Cash Flow	-6.55M
Capital Expenditures	-274,000
Free Cash Flow	-6.83M
FCF Per Share	-0.01

Full Cash Flow Statement

Margins

Gross margin is 17.59%, with operating and profit margins of -125.78% and -181.14%.

Gross Margin	17.59%
Operating Margin	-125.78%
Pretax Margin	-167.56%
Profit Margin	-181.14%
EBITDA Margin	-118.88%
EBIT Margin	-125.78%
FCF Margin	n/a

Dividends & Yields

iX Biopharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.33%
Shareholder Yield	-0.33%
Earnings Yield	-61.30%
FCF Yield	-33.60%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

iX Biopharma has an Altman Z-Score of -8.52. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-8.52
Piotroski F-Score	n/a